Bruna Oliveira de Almeida

Ms. Bruna Oliveira de Almeida


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
AGAnali Bernabe Garnique
Anali Bernabe Garnique
NPNatália Sudan Parducci
Natália Sudan Parducci
LMLivia Bassani Lins de Miranda
Livia Bassani Lins de Miranda
BABruna Oliveira de Almeida
Bruna Oliveira de Almeida
LSLeonardo Sanches
Leonardo Sanches
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
The monolayer (two-dimensional or 2D) cell culture, while widely used, lacks fidelity in replicating vital cell interactions seen in vivo, leading to a shift toward three-dimensional (3D) models. Although monolayers offer simplicity and cost-effectiveness, spheroids mimic cellular environments better. This is due to its nutrient gradients, which influence drug penetration and provide a more accurate reflection of clinical scenarios than monolayers. Consequently, 3D models are crucial in drug development, especially for anti-cancer therapeutics, enabling the screening of cell cycle inhibitors and combination therapies vital for heterogeneous tumor populations. Inhibiting processes like migration and invasion often require drugs targeting the cytoskeleton, which can exhibit dual functionality with cell cycle inhibitors. Therapeutic approaches with promising anti-cancer potential often exhibit reduced efficacy in 3D cell culture compared to their performance in monolayer settings, primarily due to the heightened complexity inherent in this system. In the face of this scenario, this review aims to survey existing knowledge on compounds utilized in both 2D and 3D cell cultures, assessing their responses across different culture types and discerning the implications for drug screening, particularly those impacting the cell cycle and cytoskeletal dynamics.

29 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KLKeli Lima
Keli Lima
LMLivia Bassani Lins de Miranda
Livia Bassani Lins de Miranda
AGAnali Bernabe Garnique
Anali Bernabe Garnique
BABruna Oliveira de Almeida
Bruna Oliveira de Almeida
MNMariane Cristina Do Nascimento
Mariane Cristina Do Nascimento
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
Significant advances in understanding the molecular complexity of the development and progression of pancreatic cancer have been made, but this disease is still considered one of the most lethal human cancers and needs new therapeutic options. In the present study, the antineoplastic effects of AD80, a multikinase inhibitor, were investigated in models of pancreatic cancer. AD80 reduced cell viability and clonogenicity and induced polyploidy in pancreatic cancer cells. At the molecular level, AD80 reduced RPS6 and histone H3 phosphorylation and induced γH2AX and PARP1 cleavage. Additionally, the drug markedly decreased AURKA phosphorylation and expression. In PANC-1 cells, AD80 strongly induced autophagic flux (consumption of LC3B and SQSTM1/p62). AD80 modulated 32 out of 84 autophagy-related genes and was associated with vacuole organization, macroautophagy, response to starvation, cellular response to nitrogen levels, and cellular response to extracellular stimulus. In 3D pancreatic cancer models, AD80 also effectively reduced growth independent of anchorage and cell viability. In summary, AD80 induces mitotic aberrations, DNA damage, autophagy, and apoptosis in pancreatic cancer cells. Our exploratory study establishes novel targets underlying the antineoplastic activity of the drug and provides insights into the development of therapeutic strategies for this disease.

28 February 2025 in Gene
Verified
Journal Article
Closed access
NPNatália Sudan Parducci
Natália Sudan Parducci
AGAnali Bernabe Garnique
Anali Bernabe Garnique
BABruna Oliveira de Almeida
Bruna Oliveira de Almeida
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto